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Abstract It has been found that CDKL5 gene mutations
are responsible for early-onset epilepsy and drug resistance.
We screened a population of 92 patients with classic/
atypical Rett syndrome, 17 Angelman/Angelman-like
patients and six idiopathic autistic patients for CDKL5
mutations and exon deletions and identified seven novel
mutations: six in the Rett subset and one in an Angelman
patient. This last, an insertion in exon 11, c.903_904
dupGA, p.Leu302Aspfx49X, is associated with a relatively
mild clinical presentation as the patient is the only one
capable of sitting and walking alone. Of the six mutations,
two are de novo missense changes affecting highly
conserved aminoacid residues, c.215 T>C p.Ile72Thr and
c.380A>G p.His127Arg (present in a mosaic condition)
found in two girls with the most severe clinical presenta-
tion, while the remaining are the splicing c.145+2 T>C and
c.2376+5G>A, the c.1648C>T p.Arg550X and the
MPLA-identified c.162_99del261 mutation. RNA charac-
terisation of four mutations revealed the aberrant transcript
of the missense allele (case 2) and not the stop mutation
(case 3), but also allowed the splicing mutation (case 1) and
the c.-162_99del261 (case 4) to be categorised as truncat-
ing. The obtained data reinforce the view that a more severe
phenotype is due more to an altered protein than haploin-
sufficiency. Furthermore, the mutational repertoire of the
CDKL5 gene is shown to be expanded by testing patients
with phenotypical overlap to Rett syndrome and applying
multiplex ligation-dependent probe amplification.
Neurogenetics (2009) 10:241–250
DOI 10.1007/s10048-009-0177-1
Electronic supplementary material The online version of this article
(doi:10.1007/s10048-009-0177-1) contains supplementary material,
which is available to authorized users.
S. Russo (*) :M. Marchi : F. Cogliati :M. T. Bonati : L. Larizza
Molecular Genetics Laboratory, Istituto Auxologico Italiano,
Via Zucchi 18-20095 Cusano Milanino (MI),
Milan, Italy
e-mail: s.russo@auxologico.it
M. Marchi
e-mail: genemol@auxologico.it
F. Cogliati
e-mail: genemol@auxologico.it
M. T. Bonati
e-mail: genemol@auxologico.it
L. Larizza
e-mail: lidia.larizza@unimi.it
M. Pintaudi : E. Veneselli
Department of Child Neuropsychiatry, G. Gaslini Hospital,
University of Genoa,
Genoa, Italy
M. Pintaudi
e-mail: mariapintaudi@hotmail.com
E. Veneselli
e-mail: edvigeveneselli@ospedale-gaslini.ge.it
V. Saletti :M. Balestrini
Unit of Developmental Neurology,
Istituto Neurologico Carlo Besta,
Milan, Italy
V. Saletti
e-mail: vsalleti@istituto-besta.it
M. Balestrini
e-mail: mrbalestrini@istituto-besta.it
B. Ben-Zeev
Sheba Med. Ctr,
Ramat-Gan, Israel
e-mail: bruria.benzeev@sheba.health.gov.il
L. Larizza
Division of Medical Genetics, San Paolo School of Medicine,
University of Milan,
Milan, Italy
Keywords Mutation screening . RNA analysis .
Genotype–phenotype correlation
Introduction
Following the description of two girls with West syndrome
(OMIM#308350) carrying X;autosome translocations dis-
rupting the cyclin-dependent kinase-like 5 gene (CDKL5;
OMIM#300203) [1], other mutations within the same gene
have been reported in patients manifesting a similar clinical
picture, thus indicating that the associated phenotype is
characterised by early-onset untreatable seizures, infantile
spasms, severe mental retardation and some features of Rett
syndrome (RTT: OMIM#312750) [2–6]. On the basis of
this clinical presentation, the CDKL5-positive group has
been assimilated to the Hanefeld early seizure variant of
RTT [2]. Bahi-Buisson [7] has recently identified an
epilepsy phenotype whose three-stage pattern begins with
“early epilepsy”, moves on to epileptic encephalopathy and
ends with late multifocal and myoclonic epilepsy.
The human CDKL5 gene product, also called serine/
threonine kinase 9 (STK9), belongs to the serine–threonine
kinase family, which shares homology with members of the
mitogen-activated protein and cyclin-dependent kinase
(CDK) families [8]. CDKL5 is a ubiquitous protein that is
mainly expressed in the brain, testes and thymus [9],
shuttling between the nucleus and cytoplasm and varying in
different brain areas and during development [10]. Its
subcellular distribution seems to be modulated by its C-
terminal tail, which is responsible for an active nuclear
export mechanism [10].
The clinical overlap between CDKL5-mutated patients
and patients with RTT, which is caused by mutations in the
Methyl-CpG-binding prote in 2 gene (MeCP2 :
OMIM#300005), prompted expression and functional stud-
ies demonstrating that CDKL5 and MeCP2 belong to the
same pathway [11, 12]. The kinase activity of CDKL5,
which bears the catalytic site in the aminoterminal region,
has been confirmed by the in vitro kinase assay and the fact
that it phosporylates MECP2, probably through intermedi-
ate signalling interactors [9, 11]. These studies have also
documented the spatial and temporal overlapping of Mecp2
and Cdkl5 expression profiles in embryonic and post-natal
mouse brain [9, 11]. Functional characterisations of human
CDKL5 mutations in both the catalytic and the large C
terminus indicate that the COOH-terminal domain nega-
tively influences kinase self-phosphorylation and coopera-
tes with the catalytic domain in regulating the nuclear
localisation of the kinase [9, 12].
Thirty-eight CDKL5 mutations have so far been de-
scribed [2, 6, 7, 13, 14], and recently, various missense
mutations have been found in three unrelated boys affected by
profound mental retardation and intractable seizures, thus
suggesting that amino acid changes in the CDKL5 protein can
be tolerated despite the hemizygous condition [15]. Given
the small number of patients, genotype–phenotype correla-
tion studies have been limited, but it has been suggested that
mutations affecting the aminoterminal catalytic domain are
associated with a more severe phenotype consisting of an
earlier onset and intractable infantile spasms followed by
late-onset multifocal and myoclonic epilepsy [7]. A more
extensive knowledge of the currently restricted CDKL5
mutational repertoire might provide new clues concerning
genotype–phenotype correlations, and analysing synthetic
derivatives of particular mutants in functional assays might
highlight new protein domains.
We here describe seven novel CDKL5 mutations
detected by screening patients with MeCP2-negativeRett
syndrome, Angelman/Angelman-like syndrome (AS), or
idiopathic autism (ADS). The sequence alterations include
whole-exons CDKL5 deletion first revealed by means of
multiplex ligation-dependent probe amplification (MLPA)
and two mutations mapping to rarely affected kinase
regions near to and downstream of the NH2 domain, the
former carried by an Angelman patient. These findings
evidence that the mutational repertoire of CDKL5 and the
associated phenotypes remain to be further disclosed.
Materials and methods
Patients
One hundred and fifteen patients with precocious epilepsy
(17 males), including 92 with classic or atypical Rett
syndrome, 17 with Angelman or Angelman-like syndrome
and six autistic patients, were recruited from local Child-
hood Neuropsychiatry Divisions. The Rett syndrome cohort
mainly included patients with the classic or the congenital
form, negative to MECP2 test. The Angelman subset
consisted of patients presenting with most major and a
few minor criteria for the syndrome (16) who proved
negative to methylation assay and UBE3A scan. Autism
was diagnosed using the ADI/ADOS interview. All of the
patients were characterised by early-onset seizures, and
most patients (including the CDKL5 mutation carriers
described below) were carefully examined by means of
serial EEG and evoked potential recordings and brain MRI.
Molecular investigations
Blood samples were collected after informed consent was
signed by the patients′ parents. MeCP2e2 mutations were
screened by means of direct sequencing using an auto-
mated sequencer (ABI PRISM 3100, PE Applied Bio-
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system, Foster City, CA, USA) and intronic exon-flanking
primers with fluorescent dye terminators designed by
Primer Express software (available on request); exon 1
of the MeCP2e1 isoform was sequenced as suggested by
Mnatzakanian et al. [17].
The Angelman/Angelman-like patients underwent meth-
ylation testing by means of M-PCR [18] and UBE3A
mutational screening and direct sequencing of the coding
region. The primers were chosen using Primer Express
software (Applied Biosystem).
For CDKL5 mutational screening, the coding and the
neighbouring intronic regions were analysed using previ-
ously described primers and conditions [19]. The PCR
products were loaded onto a Transgenomic WAVE dena-
turing high-performance liquid chromatograph, and those
showing abnormal chromatograms were sequenced on an
ABI PRISM 310.
The MECP2 and CDKL5 MLPA kit (MRC-Holland,
Amsterdam, NL) was used in accordance with the manu-
facturer′s instructions.
The methylation status of the CDKL5-mutated patients
was assessed using the Humara Androgen Receptor gene
methylation assay as previously described [20]. The triplet
repeats were separated by means of capillary electrophore-
sis and analysed using an ABI PRISM 310. Mutations
within exon 2 of the Aristaless gene (ARX) were investi-
gated using Evans′ protocol [21].
For control samples analysis was performed on periph-
eral blood DNA.
cDNA analysis of the mutations
Total RNA was extracted from fresh peripheral blood or
lymphoblastoid cell lines using the Trizol procedure (Life
Technologies, Grand Island, NY, USA), and cDNA was
obtained using the SuperScriptTM First-Strand Synthesis
System (Invitrogen Ltd, Inchinnan Business Park, UK) for
RT-PCR, with the primers being selected by Primer Express
software. Primers amplifying a product from exon 2 to exon
6 (fw: GCCATGTTTTGTGGCTTGCAT and rev:
GCTTTTTACTTTCTCAGGT) were used to characterise
the splicing mutation; primers (fw AGAAACGACTTTAC
GAGAG (ex 5) and rev GCTTTTTACTTTCTCAGGT (ex
6)) were designed for the missense mutation; and the fw
ACTCCAAGTCTGTGAGCAAC and rev CTATGCT
CAAGCTTCCATC primers in exon 12 were used for the
truncating mutation. Primers GTCCCCTGCTAGAAGTGG
within the 5′ UTR exon 1b and rev tcattttcttcactgtccttg in
exon 3 were used for the MPLA deletion aminoterminal of
isoform NM_003159.
The PCR products obtained from the cDNAs were
loaded on 3% agarose gel, eluted by GFX (Gel Heathcare,
Buckinghamshire UK) and sequenced using the above
primers in order to evaluate the presence of the aberrant
transcripts. A real-time qPCR assay was performed with the
comparative threshold cycle method and Syber Green
protocol (SYBR GREEN, PCR Master Mix, Applied
Biosystem, Warrington, UK) by using primer pairs
designed by the Primer Express software and replicated
using TaqMan probes: Hs01043900m1 (CDKL5 C-terminal
sequence) and Hs99999909 (HPRT1 ex6-7).
CDKL5 expression levels were determined on three
independent RNA preparations and triplicated readings each,
for both the test and control samples and were compared to the
internal HGPRT control gene. The threshold cycle number
(Ct) was determined for all of the PCRs, and a comparative Ct
method [22, 23] was used to calculate the related number of
alleles. The relative gene copy number was calculated by
means of the expression 2(ddCt+/-2s), which represents the
standard deviation (SD) of the difference calculated from the
Ct SD of both CDKL5 and HPRT.
Results
Ninety-two patients (including six males) characterised by
the onset of seizures in their first year of life and
refractoriness to medications were selected from a sample
of 180 patients with Rett/Rett-like phenotype, found to be
negative at MeCP2 mutation analysis (point mutations,
gross and intragenic deletions) and enrolled for CDKL5
mutational screening, together with 17 Angelman/Angelman-
like patients (six males) who were negative for all of the
known causes of 15q11.2 molecular anomalies and presented
with very early seizures and six epileptic children (five males)
diagnosed as autistic.
CDKL5 scan revealed five novel sequence alterations
and one two-exon deletion within the coding region in the
Rett patients and one novel insertion in an Angelman
patient. None of the six autistic children showed any
alteration in the CDKL5 coding sequence. The sequencing
of exon 2 of the Aristaless homeobox ARX did not reveal
any mutation in any of the CDKL5-negative cases.
Clinical evaluation of CDKL5 mutation carriers
Table 1 summarises the clinical and neurological data
relating to the seven mutated patients and includes most of
the age-related clinical signs so far reported in CDKL5
patients. All seven patients are females, had experienced a
normal perinatal period, had a normal head circumference
at birth and developed deceleration and microcephaly
within the first 2 years (except for no. 6, who did not
develop microcephaly and no. 7 who is <1 year old). They
all manifest severe intellectual disability, very limited hand
skills, hypotonia, lack of eye contact and the absence of
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speech and walking (except for 5), but only patients 6 and 7
have undergone a regressive stage.
Their seizures, which appeared by the second week of
life, were characterised by generalised activity with
multifocal spikes and without hypsarrhythmia at onset.
Three patients, 2, 4 and 5, conformed to the reported trend
of pharmacological resistance, whereas no. 1, who was
initially drug resistant, proved to be sensitive to topiramate
and has been seizure free for 2 years; no. 3 is fairly
controlled by drugs; no. 6 has slightly improved since she
started receiving levetiracetam; lastly, in no. 7, seizures
disappeared spontaneously at 6 months, and she is currently
fully controlled and out of medication. MRI was abnormal
in four of six tested patients. Additional clinical data
concerning patients 1 and 3 have been reported by Pintaudi
[14]. A few clinical traits were individual. Patient 2
experienced precocious puberty when she was 5 years
old, and she and no. 6 are the only two who are not yet able
to sit unaided. Patient 4 did not present either autonomic
features or hand stereotypies, although the deliberate use of
her hands is quite poor. Patient 5 is the first reported with
features of Angelman syndrome: She displays all the
consistent Angelman diagnostic criteria [16], i.e. absence
of speech, severe developmental delay, ataxic gait, hyper-
motoric behaviour and easily excitable personality with
uplifted hand-flapping rather than washing. She is micro-
cephalic and shows intractable generalised tonic clonic and
partial complex seizures, characterised by the slowing of
background intermittent spikes. Her facies is typical of
Angelman syndrome for brachycephaly, wide mouth and
widely dispersed teeth and progressive prognatism. She is
also autistic, but has relatively better motor skills than the
other CDKL5-mutated girls (she can walk) and has
infrequent seizures. Patient 6 is very severe and also shows
cortical blindness. Early partial complex seizures with focal
EEG changing into multifocal with developmental arrest,
normal MRI and normal extensive metabolic workup
brought us to the diagnosis of no.7.
Molecular characterisation of CDKL5 mutations
Patient 1 carries a novel splice mutation, c.145+2 T>C
(Fig. 1a) that was not found in either parent and affects the
splice donor site of exon 4. In addition to the expected
324 bp band, amplification of cDNA from exons 2 to 6
revealed a lower MW band of 278 bp (Fig. 1c). The
aberrant transcript seems to be well represented as shown
by the intensity of the band on agarose gel and the peak
control/mutant ratio when the PCR products are separated
by capillary electrophoresis (not shown), which is consis-
tent with random X inactivation (50%). The sequencing of
this aberrant band showed exon 4 skipping (Fig. 1b), which
indicates that the alteration in the IVS4 donor site probablyS
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makes the IVS3 donor site refer directly to the IVS4
acceptor without using the IVS3 acceptor (Fig. 1d). The
new junction predicts an alteration in the translational frame
as a result of the introduction of 59 aberrant amino acids
and a stop codon after Lys33 leading to premature
truncation of the protein, p.Glu34LysfxX60.
Patient 2 carries a de novo T>C substitution, c.215 T>C
p.Ile72Thr, affecting nt 215 of the coding sequence and
leading to the replacement of isoleucine72 by threonine
(Fig. 2a). A high degree of evolutionary conservation is
shown for Ile72 by protein sequence alignment (data not
shown). Analysis of the cDNA revealed a small peak for
the mutant allele (Fig. 2b), although X inactivation seemed
to be balanced and reproducible also in the lymphoblastoid
cell line (data not shown). Quantification in the latter of the
amount of CDKL5 by real-time PCR showed a transcript
level only slightly lower as compared to the control (data
not shown)
Patient 3 carries a de novo c.1648C>T p.Arg550X
mutation that predicts the conversion of Arg 550 to a stop
codon leading to a truncated protein. In accordance with the
rule that an aberrant transcript carrying a stop codon more
than 50 bp from the splicing site undergoes mRNA-
mediated decay, cDNA analysis showed that the mutated
allele was not represented as only the normal allele was
detected (data not shown). Real-time PCR on the lympho-
blastoid cell line, which showed a balanced X inactivation
likewise the peripheral blood, demonstrated a 50% level of
transcript when compared to control, so confirming the
decay of the mutant mRNA.
Fig. 2 Genomic (a) and cDNA (b) electropherograms of the missense
c.215 T>C p.Ile72Thr mutation
Fig. 1 Electropherograms of
the splicing c.145+2 T>C
mutation found in patient 1; on
peripheral blood genomic (a)
and cDNA(b); (c) agarose run
evidencing both mutant (M) and
control (C) transcripts; (d) puta-
tive splicing mechanism allow-
ing the exclusion of exon 4
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In patient 4, the mutation c.-162_99del261 was identi-
fied by means of the MLPA test, which was applied to all
CDKL5-negative patients in order to detect intragenic
deletions/duplications. Normalisation of the peak areas
identified halved values for the probes corresponding to
exons 2 and 3 (Fig. 3a), and PCR of cDNA using a primer
mapping within the 5′ UTR exon of the NM_003159
isoform and the other downstream exon 4 revealed a
deletion of 261 bp (Fig. 3b). Sequencing of the aberrant
transcript confirmed that the whole sequence of exons 2
and 3 was missing (Fig. 3c). This deletion does not alter the
reading frame, but removes the original ATG. Several
ATGs are present in the newly formed sequence, but all
predict the creation of reading frames with premature stop
codons.
In patient 5, a de novo insertion of two nt was identified
in exon 11, c.903_904 dupGA, which causes a stop codon
49 amino acids downstream, p.Leu302Aspfx49X (data not
shown). No RNA was available precluding cDNA analysis.
In patient 6, an A>G transition was detected in exon 6 at
nt 380, leading to the replacement of His127 by Arg
(p.His127Arg). The affected residue, which shows a high
degree of evolutionary conservation (not shown), belongs to
the active serine–threonine kinase site. The sequence
alteration was not found in either parent and >100 X
chromosomes from normal individuals and was not observed
in any of the other patients enrolled in this study. On the basis
of its peak height (Fig. 4), it seems to be in a mosaic
condition. We found the same electropherogram profile on
fibroblasts’ DNA (data not shown). No RNA was available
for transcript analysis.
In patient 7, a G>A transition was found in the fifth
nucleotide of the acceptor consensus of IVS16 c.2376+5G>
A (supplementary figure on line); splice view software
reveals that the consensus sequence is abolished by the
substitution, thus leading to missplicing. The de novo
origin of the mutation was confirmed, and we could rule
out the observed alteration in 100 controls. RNA was not
available for further studies.
A number of SNPs were detected and are summarised in
Supplementary Table 2 (online), including an unreported
Fig. 3 a MLPA results: The
two bars corresponding to the
deleted exons 2 and 3 are
arrowed; b electrophoresis of
peripheral blood cDNA (lane 1
patient, M, lanes 2 and 3 con-
trols, C) shows in the patient the
deleted (119 bp) and the
expected (380 bp) bands; c
cDNA sequencing defines ex-
actly the deletion, joining the
last base of exon 1 to the first
base of exon 4
Fig. 4 Mosaicism of c.380A>G mutation is evidenced by the
different height of peaks visible both in forward (a) and reverse (b)
sequence
Neurogenetics (2009) 10:241–250 247
coding c. 2767C>T p.Arg923Cys, and the previously
reported coding p.Gln791Pro variant [22]. A patient carrying
two silent substitution, p.Hys1001His and p.Thr1028Thr, in
exon 21 plus the intronic variant c.404-53 T>C in IVS6 was
found. All the polymorphisms were maternally inherited;
evaluation of X inactivation showed that all are balanced.
Additional five intronic and one 3′ UTR variant are shown,
but their origin could not be established because of parental
refusal.
Figure 5 provides an updated overview of all of the
published (including balanced) translocations found to disrupt
the CDKL5 gene [23] and our CDKL5 mutations. Mutations
span the whole gene and in terms of the types of mutation, 21
are truncating, ten are splice site and 13 are missense
mutations, of whom three in male patients [15]. A mutation
hotspot is apparent at codon 172, where we identified a novel
change (p.Ile72Thr) in patient 2, while the p.His127Arg
carried by our patient 6 in a mosaic condition is the only
missense mutation in the serine–threonine kinase domain.
Our case 4 mutation, involving the deletion of two whole
exons and the ATG codon, is difficult to classify.
Discussion
We screened CDKL5 mutations in patients with three
neurodevelopmental disorders (RTT, AS and ADS) sharing
the common features of early-onset and drug-resistant
seizures.
AS and AS-like enter in differential diagnosis with RTT,
a phenotypical overlap which was first indicated by the
finding of five MeCP2 mutated cases (four females and one
male) in a cohort of 47 AS patients (25 females and 22
males) with no molecular 15q11-13 anomaly [24]. A few
studies have recommended extending CDKL5 screening to
patients with a shared clinical phenotype, including AS and
Fig. 5 Schematic representation of the CDKL5 gene with its 21
exons. All the mutations reported in the literature are placed in the
proper position on the gene, including those (in blue) recently
identified in males. Truncating and splice mutations are indicated
with cDNA nomenclature and missense mutations with protein
nomenclature. Mutations detected by this study are in purple. At the
bottom, schematic of the CDKL5 protein with its known functional
domains (11)
248 Neurogenetics (2009) 10:241–250
AS-like patients [19, 22], but no mutated cases have been
previously identified. The patient described by Tao carrying
a p.Cys152Phe was also tested for methylation pattern, but
she has a clinical picture more severe than an Angelman
patient [22]. Our patient 5, who fulfilled the main criteria
for AS [16], is the first shown to carry a CDKL5 gene
mutation. The finding of CDKL5 mutations in two cases
with an Angelman-like phenotype supports the view that
the screening of CDKL5 in such patients might be
successful. Our decision to include a few autistic patients
fulfilling the inclusion criterion of early-onset epilepsy was
based on the shared autistic traits of AS and ADS cases and
the reported finding of a CDKL5 mutation in one autistic
patient [13]. A larger sample of autistic patients with early-
onset seizures needs to be examined in order to establish
the involvement of CDKL5 in this subset.
Our exhaustive molecular analysis not only included
sequencing the whole coding sequence and exon-flanking
regions but also the MLPA screening of whole exon
deletions/duplications in a subgroup of patients with
negative CDKL5 scan results, which identified one deleted
patient (case 4) and indicates that at least a few CDKL5
mutations are not detected by standard mutational screening
methods. The frequency of CDKL5 mutations in the
selected cohorts is 7.6%, concordant with that reported by
Bahi-Buisson (8.1%) for patients with refractory epilepsy
[6], which has been the main selection criterion for our
cohorts and much less than that found for children with
infantil spasms (16.7%) [6].
Our findings increase the relatively restricted repertoire
of CDKL5 mutations (38 prior to this study) by a further
seven, including two missense, two splicing, one apparently
in-frame deletion identified by MLPA and two stop
mutations (Fig. 5). Four of these mutations affect the
predicted NH2-terminal catalytic domain ending at residue
297; the p.Leu302AspfsX49 mutation (patient 5) maps just
downstream, while the p.Arg550X (patient 3) and c.2376+
5G>A (patient 7) mutations affect a scarcely involved
kinase region. It may not be coincidental that the seizures of
patient 3 have been controlled by drugs for 3 years and
disappeared in patient 7, thus indicating a less severe
evolution of the disease, while patient 5 (enrolled in the
AS–AS-like group) is able to sit up alone and walk. These
observations are in line with a recent study indicating that a
less severe phenotype is associated with mutations in the
second part of the protein [7]. It is also worth noting that
the two described stop mutations probably undergo RNA
nonsense-mediated decay and we proved this for p.
Arg550X as no mutant RNA was found by RT-PCR. On
the contrary, both of our de novo missense mutations are
associated with a very severe clinical presentation, and the
RT-PCR detection of the transcript for p.Ile72Thr makes it
plausible to hypothesise that an aberrant protein may be
more harmful than its absence. The finding of a small peak
for the mutated allele by sequencing may be accounted for
by the low sensitivity of this method to reveal the reduced
amount of transcript. In our small series of CDKL5-mutated
patients, we observed that the stop codon mutation carriers
have a milder phenotype than those with missense or
splicing mutations. Our patient 6 carries p.His127Arg, the
first mosaic CDKL5 mutation described so far and the only
missense mutation affecting the active serine–threonine
kinase site and shows clear regression and severe hypoto-
nia, but no microcephaly; furthermore, the severity of her
phenotype parallels that of patient 2, who bears the
missense mutation p.Ile72Thr, which involves a residue
that may represent a small mutational hotspot affecting the
catalytic kinase site. Indeed, the p.Ile72Thr mutation of
patient 2 is the third affecting Ile72 to be discovered. A
different change (p.Ile72Asn) was reported by Evans [21]
and a silent change (p.Ile72Ile) was observed in a Chinese
Rett cohort [4] and has so far been excluded as a
polymorphism.
An examination of both our missense sequence changes
using the splice-site prediction programme (ESE Finder
release 2.0: http://rulai.cshl.edu/tools/ESE) predicts that
these mutations do not significantly alter exonic splicing
enhancer sites, thus suggesting that the aberrant transcripts
can be translated into aberrant proteins. A severe phenotype
has recently been reported in the case of two other missense
mutations leading to mislocalised protein, which the
authors suggested may be due to disruption caused by the
amino acid substitution of nuclear import domains [5].
RT-PCR and sequencing allowed us to classify the
splicing mutation of patient 1 as a truncating mutation,
but the fact that the aberrant truncated transcript could be
observed suggests that the shorter mutated allele does not
undergo nonsense-mediated RNA decay. This mutation,
that we already described [14], has been recently reported
in another patient [6] who is defined as an atypical Rett.
Our patient is similar in the most frequent features, but
differs for seizure onset, autonomic features and sleep
disturbance. The c.145+2 T>C mutation may thus pinpoint
another mutation hotspot. In the case of the deletion
identified by MLPA (patient 4), transcript analysis showed
that aberrant transcripts in which the first two coding exons
are deleted together with the initial ATG site also escape
RNA decay. However, despite that a mutant transcript could
be observed, biocomputer tools did not reveal any
alternative ATG sites predicting a translatable protein. It
seems that classifying mutations at DNA level may
sometimes be insufficient to predict their consequences
and address genotype–phenotype correlations.
In conclusion, bioinformatic analysis of CDKL5 mutations,
coupled to RNA analysis on fresh blood or X inactivation
profile-matched lymphoblastoid cell lines, constitute the
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necessary prerequisite to fully address the genotype–
phenotype correlation in CDKL5 mutated female carriers.
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